Fresenius Kabi’s Idacio (adalimumab, biosimilar) Receives EU’s Marketing Approval in Rheumatology, Gastroenterology and Dermatology

Shots:

• The approval is based on its non-inferiority data consisting of its PK, efficacy, safety, immunogenicity data with the reference product in analytical, preclinical and clinical data trials
• Fresenius Kabi has a portfolio consisting of generic drugs, infusion therapies, biosimilars, and clinical nutrition products focusing on multiple therapy areas
• Idacio (adalimumab, biosimilar) is a mAb and is indicated for Rheumatoid arthritis (RA), Juvenile Idiopathic Arthritis, Axial Spondyloarthritis, psoriatic arthritis, plaque psoriasis, adult & pediatric Crohn’s disease and ulcerative colitis

Click here to read full press release/ article | Ref: Fresenius Kabi | Image: Behance